Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-B2302 vs bevacizumab plus paclitaxel/carboplatin in first-line non-squamous NSCLC
CTR20180857Phase 3Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of GB222 in Non-small cell lung cancer (NS-NSCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jul 2018; status: completed.
02
Drugs
GB222
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20180857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180857.